Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Onyx, TRUFILL · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Onyx | EXPERIMENTAL | - |
| TRUFILL | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Onyx | DEVICE | Embolization |
| TRUFILL | DEVICE | Embolization |
Inclusion Criteria: * The patient or patient's guardian understands and will sign the informed consent for the procedure * The patient has a confirmed diagnosis of a brain AVM in the cerebral cortex, cerebellum or dura mater as visualized by angiography or cross sectional imaging. * The brain AVM h...
Onyx and TRUFILL are liquid embolic agents used to treat brain arteriovenous malformations (AVMs), abnormal tangles of blood vessels in the brain. They are injected into the malformation to block blood flow. Both are being studied in a Phase 2 clinical trial for this condition.
Onyx and TRUFILL are developed by Medtronic plc., a medical technology company. Medtronic is publicly traded on the New York Stock Exchange under the ticker symbol MDT.
Onyx and TRUFILL are in Phase 2 clinical development for brain arteriovenous malformations. The Phase 2 trial has been completed. They are investigational agents and have not been approved for this indication based on the available data.
Onyx and TRUFILL are being evaluated in a completed Phase 2 clinical trial with the identifier NCT00857662. The study, titled "Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs)," enrolled 117 participants in the United States and used an active-controlled design.
Onyx and TRUFILL are two different liquid embolic agents being compared against each other in a clinical trial for brain arteriovenous malformations. The trial is designed to compare the two treatments directly, indicating they are distinct products with potentially different characteristics.